Immunostimulant

3 Drugs classified under this drug class

Immunostimulant. Mifamurtide 4 mg/vial.
VIAL (pwdr. for concentrate. for dispers. for infus.): 1×4 mg. After reconstit. to final volum. of 50 ml, each ml of suspens. contains 0.08 mg mifamurtide.
Pts. 2-30 yrs.: 2 mg/m² bdy. surf. As adjuvant ther. follow. resect.: twice wkly. at least 3 d apart for 12 wks., follow. by once wkly. tmts. for an addit. 24 wks. for a total of 48 infus in 36 wks. For special populat. See lit.
Tmt. in child., adolesc. & young adult. with. high grade, resectab., nonmetastat. osteosarcoma aft. macroscopic. Complete surg. resect. In combinat. with post-op. multi-agent chemother. Safety and effic. assessed in pts. 2-30 yrs at init. diagn.
C/I: Hypersens., Concurr. use with cyclosporine/other calcineurin inhibit., high-dose NSAIDs, cyclooxygenase inhibit.

Immunostimulant. Plerixafor 24 mg / 1.2 ml.
VIAL: 1. 0.24 mg/kg bdy weight/ dly,
admin S.C. inject. 6-11 hrs prior to
initiat. of apheresis follow. 4 day pretmt.
with granulocyte-colony stimulat.
factor (G-CSF).
In combinat. with G-CSF to enhance
mobilisat. hematopiet. stem cells to
periph. blood for collect. and subseq.
autologous transplant. in pts. with
lymphoma and multiple myeloma.
C/I: Hypersens.

Immunostimulant. Bacillus Calmette-Guérin (BCG) 2-8X10^8 CFU.
VIAL: 1, 3. See lit.
Tmt. flat urothelial cell carcinoma in situ
(CIS) of the bladder, adjuv. ther. aft.
transurethral resect. (TUR) of a primary or relaps. fic. papill. urothelial cell carcinoma
of the bladder stage Ta (grade 2 or 3) or T1
(grade 1, 2, 3). See lit. Maint. tmt. all pts:
Wkly instill. for 3 consec. wks at mths 3, 6
and 12 aft. initiat. See lit.